Prime Peptides
primepeptides.co ↗Company Overview
Prime Peptides (primepeptides.co) is a California-based research peptide company operating as Prime Vitality, Inc. from Santa Barbara, CA (735 State St, Ste 524). The company sells injectable research peptides with COAs available on their testing page. They position themselves around quality, fast shipping, and responsive customer service.
Important: Do not confuse with Prime Lab Peptides (primelabpeptides.com), which is a separate, Miami-based company founded in 2025 with 702 Trustpilot reviews at 5 stars.
Regulatory Standing — FDA Warning Letter
Score: 25/100 — On December 10, 2024, the FDA issued a warning letter to Prime Vitality, Inc. (doing business as Prime Peptides). This is documented on their BBB profile.
The FDA found that Prime Peptides was selling semaglutide, tirzepatide, and retatrutide — products that constitute unapproved new drugs under sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act.
Key findings from the FDA warning letter:
- FDA reviewed Prime Peptides’ website and social media, finding products marketed for human use
- Despite “research purposes only” and “not for human consumption” labeling, evidence from the website established products were intended as drugs for human use
- Products included semaglutide (active ingredient in Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide (Lilly’s experimental GLP-1)
- Company was given 15 working days to take corrective action
- This warning letter was part of a broader FDA crackdown targeting Xcel Peptides, SwissChems, Summit Research, and Prime Peptides simultaneously
The FDA Intended Use Doctrine is clear: disclaimers do not override evidence of intended human use derived from website content, marketing materials, and social media.
Quality & Testing
Score: 55/100 — Prime Peptides claims third-party testing on all batches with COAs available on their testing page. One Trustpilot reviewer noted lot numbers on vials did not initially match published COAs, but after contacting support, the company provided the matching COA showing 99.72% purity.
Not in Finnrick database: No independent Finnrick Analytics data available.
The willingness to respond with matching COAs is a positive sign, though the initial mismatch between vial lot numbers and published COAs suggests the testing page may not always be current.
Customer Experience
Score: 55/100
- Trustpilot: 41 reviews, generally positive. Customer service is frequently praised — named representative “Karissa” appears responsive
- BBB: Listed as Prime Vitality, Inc. BBB does not have sufficient information to issue a rating. The FDA warning letter is prominently displayed on the BBB profile
- Multiple reviewers mention fast shipping (2-day delivery)
- Some checkout/payment processing issues noted
- One customer reports losing 60+ pounds — clearly human consumption, contradicting “research only” positioning
Pricing
Score: 55/100 — Mid-range pricing. No bulk discount program visible. Standard for California-based peptide vendors.
Red Flags
- FDA Warning Letter (Dec 2024): Formal enforcement action for selling unapproved drugs (semaglutide, tirzepatide, retatrutide)
- Intended use evidence: FDA found website/social media content contradicts “research only” labeling
- Customer reviews confirm human use: Trustpilot reviews openly discuss weight loss results — further undermining research-only positioning
- COA lot number mismatch: At least one documented case of vial lot numbers not matching published COAs (resolved after contact)
- Part of broader FDA crackdown: Named alongside SwissChems, Xcel Peptides, and Summit Research in December 2024 enforcement wave
Positives
- COAs available: Testing page with certificates; company responsive to COA requests
- Named US address: Verifiable Santa Barbara, CA location
- Responsive customer service: Consistent praise across review platforms
- Fast shipping: Same-day shipping for orders before 2 PM cited by multiple reviewers
- Credit card accepted: Payment processor vetting provides some baseline legitimacy signal
The PeptideExaminer Verdict
Prime Peptides demonstrates some genuine quality infrastructure — published COAs, responsive customer service, verifiable US address, and credit card acceptance. However, the December 2024 FDA warning letter for selling semaglutide, tirzepatide, and retatrutide as unapproved drugs is a serious mark that cannot be overlooked.
The company’s grade is pulled down primarily by the FDA enforcement action and the transparent contradiction between “research only” labeling and abundant evidence of human-use marketing. If Prime Peptides can demonstrate they’ve responded to the FDA warning by removing GLP-1 products and tightening marketing language, a future grade revision upward would be warranted.
Grade: C-
| Category | Score | Weight | Weighted |
|---|---|---|---|
| Transparency | 50 | 20% | 10.0 |
| Testing | 55 | 25% | 13.75 |
| Pricing | 55 | 15% | 8.25 |
| Reputation | 55 | 20% | 11.0 |
| Compliance | 25 | 20% | 5.0 |
| Total | 48.0 → C- |
Sources: FDA.gov Warning Letters, BBB.org (Prime Vitality, Inc.), Trustpilot, primepeptides.co